{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T11:12:54Z","timestamp":1740136374533,"version":"3.37.3"},"reference-count":6,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,11,4]],"date-time":"2022-11-04T00:00:00Z","timestamp":1667520000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,11,4]],"date-time":"2022-11-04T00:00:00Z","timestamp":1667520000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Sci"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1007\/s10072-022-06481-2","type":"journal-article","created":{"date-parts":[[2022,11,4]],"date-time":"2022-11-04T15:03:15Z","timestamp":1667574195000},"page":"1093-1095","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Recurrent skin infections associated with natalizumab treatment"],"prefix":"10.1007","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0537-1340","authenticated-orcid":false,"given":"Daniela Santos","family":"Oliveira","sequence":"first","affiliation":[]},{"given":"Ana Rita","family":"Castro","sequence":"additional","affiliation":[]},{"given":"Lu\u00eds","family":"Ruano","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2022,11,4]]},"reference":[{"issue":"6","key":"6481_CR1","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1136\/jnnp-2019-322326","volume":"91","author":"H Butzkueven","year":"2020","unstructured":"Butzkueven H et al (2020) \u201cLong-term safety and effectiveness of natalizumab treatment in clinical practice: 10 years of real-world data from the Tysabri Observational Program (TOP)\u201d, (in eng). J Neurol Neurosurg Psychiatry 91(6):660\u2013668. https:\/\/doi.org\/10.1136\/jnnp-2019-322326","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"5","key":"6481_CR2","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1002\/ana.20859","volume":"59","author":"M Niino","year":"2006","unstructured":"Niino M et al (2006) \u201cNatalizumab effects on immune cell responses in multiple sclerosis\u201d, (in eng). Ann Neurol 59(5):748\u2013754. https:\/\/doi.org\/10.1002\/ana.20859","journal-title":"Ann Neurol"},{"key":"6481_CR3","doi-asserted-by":"publisher","first-page":"549842","DOI":"10.3389\/fimmu.2020.549842","volume":"11","author":"K Khoy","year":"2020","unstructured":"Khoy K, Mariotte D, Defer G, Petit G, Toutirais O, Le Mauff B (2020) \u201cNatalizumab in multiple sclerosis treatment: from biological effects to immune monitoring\u201d, (in eng). Front Immunol 11:549842. https:\/\/doi.org\/10.3389\/fimmu.2020.549842","journal-title":"Front Immunol"},{"issue":"6","key":"6481_CR4","doi-asserted-by":"publisher","first-page":"2514","DOI":"10.4049\/jimmunol.1403246","volume":"196","author":"SA Geherin","year":"2016","unstructured":"Geherin SA, G\u00f3mez D, Glabman RA, Ruthel G, Hamann A, Debes GF (2016) \u201cIL-10+ innate-like B cells are part of the skin immune system and require \u03b14\u03b21 integrin to migrate between the peritoneum and inflamed skin\u201d, (in eng). J Immunol 196(6):2514\u20132525. https:\/\/doi.org\/10.4049\/jimmunol.1403246","journal-title":"J Immunol"},{"key":"6481_CR5","unstructured":"(2021) Tysabri (natalizumab) prescribing information. [Online] Available:\u00a0https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/125104s973s975lbl.pdf. Accessed 2 Feb 2022"},{"issue":"5","key":"6481_CR6","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1177\/1352458512460604","volume":"19","author":"A Vennegoor","year":"2013","unstructured":"Vennegoor A et al (2013) \u201cClinical relevance of serum natalizumab concentration and anti-natalizumab antibodies in multiple sclerosis\u201d, (in eng). Mult Scler 19(5):593\u2013600. https:\/\/doi.org\/10.1177\/1352458512460604","journal-title":"Mult Scler"}],"container-title":["Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-022-06481-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10072-022-06481-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-022-06481-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T00:25:58Z","timestamp":1676334358000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10072-022-06481-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,4]]},"references-count":6,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["6481"],"URL":"https:\/\/doi.org\/10.1007\/s10072-022-06481-2","relation":{},"ISSN":["1590-1874","1590-3478"],"issn-type":[{"type":"print","value":"1590-1874"},{"type":"electronic","value":"1590-3478"}],"subject":[],"published":{"date-parts":[[2022,11,4]]},"assertion":[{"value":"8 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 October 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Approval was obtained from the ethics committee of Centro Hospitalar de Entre o Douro e Vouga. The procedures used in this study adhere to the tenets of the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The participant has consented to the submission of the full content of the case report to the journal.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent"}},{"value":"None.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}